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Background: Electrical cardioversion (CV) is essential in rhythm management of atrial fibrillation
(AF). However, optimal timing of CV remains unknown.
Hypothesis.: Timing of CV in AF is associated with risk of adverse events.
Methods: We analyzed the effect of AF episode duration on safety and efficacy of electrical CV
in a multicenter, multicohort study exploring 4356 CVs in 2530 patients on oral anticoagulation.
The composite adverse outcome included unsuccessful CV, acute arrhythmic complications,
thromboembolic events, mortality, and AF recurrence within 30-day follow-up.
Results: Study groups were stratified according to duration of index AF episode (<24 h,
24–48 h, 48 h–30d, and > 30d), consisting of 1767, 516, 632, and 1441 CVs, respectively. CVs
were unsuccessful in 8.5% (<24 h), 5.4% (24–48 h), 11.1% (48 h–30d), and 13.9% (>30d),
respectively (P < 0.01). Occurrence of thromboembolic events (0.1%), mortality (0.1%), and asys-
tole >5 seconds (0.7%) within 30-day follow-up was infrequent and comparable in the study
groups. AF recurrence within 30 days after initially successful CVs was 29.8% (<24 h), 26.5%
(24–48 h), 37.3% (48 h–30d), and 30.3% (>30d), respectively (P < 0.01). Composite adverse out-
come occurred in 1669 (38.4%) CVs, and index AF episode >48 hours was an independent pre-
dictor for the composite endpoint (OR: 1.49, 95% CI: 1.28–1.74, P < 0.01) in multivariate
analysis.
Conclusions: Optimal timing of CV for AF showed a J-shaped curve, with fewest adverse out-
comes in patients with CV performed 24 to 48 hours after onset of AF. In patients with rhythm-
control strategy, delaying CV >48 hours is associated with increased risk for adverse outcomes.
KEYWORDS
Arrhythmic Complications, Atrial Fibrillation, Cardioversion, Recurrence, Success Rate,
Thromboembolism
1 | INTRODUCTION
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, and it
is estimated that every fourth middle-aged adult will ultimately
develop AF during their lifespan.1 Electrical cardioversion (CV) has
remained the cornerstone of rhythm-control management of AF for
decades and is widely used in symptomatic patients despite the lack
of evidence of any survival benefit.2–4 In previous studies, longer
duration of AF episode increased the possibility of unsuccessful CV
and stroke.5–7 However, little is known regarding efficacy and safety
of CV with different AF episode lengths in patients on oral anticoagu-
lation (OAC). Therefore, we sought to investigate the optimal timing
of CV for AF in this multicenter study.
2 | METHODS
The Safety of Cardioversion of Acute Atrial Fibrillation (Finnish Car-
dioVersion [FinCV]) studies constitute an observational study program
exploring thrombotic and bleeding complications of AF after electri-
cal CV.6–9
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The present study cohort was gathered from datasets of the
FinCV (http://www.ClinicalTrials.gov NCT01380574), the FinCV2
(http://www.ClinicalTrials.gov NCT02850679), and the FinCV3
(http://www.ClinicalTrials.gov NCT02911545) study populations.
Data were collected from patient registries at 3 university hospitals,
2 central hospitals, and 3 regional hospitals from the time periods of
2003–2010, 2003–2015, and 2011–2016 in the FinCV, FinCV2, and
FinCV3 studies, respectively. The details of the catchment areas of
each study have been described in detail previously.7,8,10 Initially,
patient registries were screened in each hospital for International Clas-
sification of Diseases, Tenth Revision (ICD-10) code I48 (AF) and for
Nordic Classification of Surgical Procedures (NCSP) code TFP20 (cardio-
version). Patients were then included in each study according to speci-
fied inclusion criteria: all patients admitted to the emergency
department because of an acute (<48 h) AF in whom electrical or
pharmacological CV was attempted (FinCV); all patients with persis-
tent (>48 h) AF in whom elective electrical CV was attempted
(FinCV2); and all patients with AF using non–vitamin K oral anticoagu-
lants (NOAC) in whom electrical or pharmacological CV was
attempted (FinCV3). Altogether, these studies comprised 5441
patients and 10 852 CVs.
Only patients on OAC, either vitamin K antagonist or NOAC, prior
to electrical CV for AF were included in the present analysis. Patients
undergoing pharmacological CV and those with unavailable data on
the duration of the index AF episode were excluded. The final study
cohort included a total of 2530 patients and 4356 CVs (Figure 1).
Patients were divided into 4 groups according to the duration of index
episode of AF: <24 hours, 24 to 48 hours, 48 hours to 30 days,
and > 30 days.
All patient data were collected from patient records using a struc-
tured electronic case-report form consisting of general disease and AF
history and medications.
The primary endpoint of this study was a composite adverse out-
come defined as the occurrence of any of the following events: death,
thromboembolic (TE) event, unsuccessful CV, and acute arrhythmic
complication and/or AF recurrence within the 30-day follow-up. The
inability to maintain sinus rhythm until discharge despite initially suc-
cessful CV was considered an unsuccessful CV. Asystole lasting
>5 seconds, ventricular tachycardia, or ventricular fibrillation immedi-
ately after the CV were considered acute arrhythmic complications. A
TE event was classified as an ischemic nonhemorrhagic stroke adjudi-
cated by the treating neurologist and imaging. Occurrence of AF
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FIGURE 1 Flow chart showing patient cohort selection
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within 30 days after a successful index CV confirmed by electrocar-
diogram or pacemaker log was defined as an AF recurrence.
All AFs were confirmed by the clinician performing the procedure
based on electrocardiographic findings. AF and atrial flutter were not
segregated. CVs were performed according to the contemporary
guidelines in general anesthesia. The positioning of the paddles or
pads (anteroposterior or anterolateral configuration) was at the discre-
tion of the clinician. The energy ranged from 70 J to 360 J with
monophasic and 70 J to 200 J with biphasic defibrillator devices.
Biphasic defibrillators were used after 2004.
The study received approval of the Medical Ethics Committee of
the Hospital District of Southwest Finland and the ethics committee
of the National Institute for Health and Welfare. The study conforms
to the Declaration of Helsinki. Informed consent was not required
because of the retrospective nature of the study.
2.1 | Statistical analysis
Normally distributed continuous variables were reported as mean
SD, whereas skewed continuous variables were denoted as median
(interquartile range). Normality in continuous covariates was tested
with Kolmogorov–Smirnov and Shapiro–Wilk tests. Categorical vari-
ables were reported as counts and percentages. The unpaired t test or
Mann–Whitney test was used to compare continuous variables and
the Pearson χ2 or Fisher exact test to compare categorical variables in
the study subgroups, as appropriate. Logistic regression with back-
ward selection was used to identify the independent predictors of
adverse events. Baseline variables with P < 0.10 level in univariate
analysis were entered into the logistic regression models. The
Hosmer-Lemeshow test was used to estimate the calibration of the
regression models. All tests were 2-sided, and P < 0.05 was consid-
ered statistically significant. SPSS Statistics software, version 22.0
(IBM Corp., Armonk, NY), was used to perform all analyses.
3 | RESULTS
Altogether, 1767, 516, 632, and 1441 CVs were performed for index
AF episodes lasting <24 hours, 24 to 48 hours, 48 hours to 30 days,
and > 30 days, respectively. Baseline characteristics of each patient
group are depicted in Table 1. Patients with shorter index AF episode
duration (<24 h or 24–48 h) were more likely to be female and have a
history of hypertension, coronary artery disease, peripheral arterial
disease, prior stroke or myocardial infarction, or antiarrhythmic medi-
cation. Patients with longer AF episodes (48 h–30 d or > 30 d) had
lower CHA2DS2-VASc scores and ventricular rate at the time of CV,
but they were more likely to have a history of congestive heart failure
or chronic kidney disease.
The associations between index AF episode duration and adverse
outcomes are summarized in Table 2. A total of 448 (10.3%) CVs were
unsuccessful. The relationship between AF episode duration and
unsuccessful CV showed a J-shaped curve (Figure 2). Patients with AF
episodes lasting 24 to 48 hours had the lowest rate of unsuccessful
CVs. In multivariate analysis, >48-hour duration of index episode of
AF independently predicted unsuccessful CV (odds ratio [OR]: 1.79,
95% CI: 1.41–2.26, P < 0.01). Asystole lasting >5 seconds was
detected after 32 (0.7%) CVs, and there were no differences in the
occurrence of asystole >5 seconds between the groups.
Within 30 days of follow-up, 4 (0.1%) patients died and 5 (0.1%)
definite TE events were observed. None of the studied covariates
were associated with an increased risk of TE events. An early recur-
rence of AF was detected after 1194 (30.6%) initially successful CVs
within the 30-day follow-up. Patients with shorter AF episode dura-
tion (<24 h and 24–48 h) had lower risk for recurrence, whereas an
index AF episode lasting >48 hours was an independent predictor of
AF recurrence (OR: 1.38, 95% CI: 1.16–1.64, P < 0.01).
Altogether, composite adverse outcomes occurred after 1669
(38.4%) CVs within 30-day follow-up, and the risk of adverse events
was lowest in patients with an index AF episode lasting 24 to
48 hours (Figure 2). An index episode of AF lasting >48 hours (OR:
1.49, 95% CI: 1.28–1.74, P < 0.01), congestive heart failure (OR: 1.52,
95% CI: 1.22–1.89, P < 0.01), chronic kidney disease (OR: 1.56, 95%
CI: 1.07–2.27, P = 0.02), peripheral arterial disease (OR: 1.23, 95% CI:
1.01–1.49, P = 0.04), β-blocker medication (OR: 1.43, 95% CI:
1.16–1.76, P < 0.01), and antiarrhythmic medication at discharge (OR:
1.73, 95% CI: 1.46–2.05, P < 0.01) independently predicted the devel-
opment of composite adverse outcome in multivariate analysis.
In an additional analysis, the study patient cohort with known
duration of the index AF episode was compared with the excluded
patient cohort with uncertain duration of the index AF episode (see
Supporting Information, Table S1, in the online version of this article).
The patients with AF episodes of uncertain duration were generally
healthier, more often female, and less often had prior history of AF or
medications. The rate of unsuccessful CVs was higher (17.5% vs
10.3%; P < 0.01), but fewer (0.1% vs 0.7%; P = 0.03) episodes of asys-
tole lasting >5 seconds occurred in the excluded patient cohort com-
pared with the study patient cohort, respectively. There were no
other differences between the groups in the other efficacy or safety
endpoints of the composite adverse outcome.
4 | DISCUSSION
The present large multicenter study demonstrated that the risk for
adverse outcomes after CV was doubled in patients with an index AF
episode >48 hours when compared with patients with a shorter dura-
tion of AF before CV, irrespective of other predictors of CV failure
and complications. Concordantly, rates of unsuccessful CVs and recur-
rences of AF within 30-day follow-up after CV were lowest in the
patient group with AF episode lasting 24 to 48 hours. The occurrence
of safety endpoints (eg, TE events, mortality, and episodes of asystole
[>5 s] after CV) was low and spread evenly among patient groups.
These observations support the view that performing CV early is bet-
ter than delaying it when aiming at rhythm control.
It was not a surprise that there were fewer unsuccessful CVs
among patients with acute AF episodes. The overall rates of unsuc-
cessful CVs and recurrences of AF within the 30-day follow-up were
in line with previous studies.5,11–14 The relationship between AF epi-
sode duration and rate of unsuccessful CV is also in agreement with
previous studies,5,7,15 whereas the predictors for AF recurrence after
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CV have been inconsistent11,13–16 and no association between the
episode duration and recurrence rate of AF has been observed previ-
ously. However, prior studies were based on small patient popula-
tions, and they were less balanced with respect to AF episode
duration. Importantly, in our study only 5% of CVs performed for AF
lasting 24 to 48 hours were unsuccessful, whereas the patient group
with the shortest AF episodes had slightly more unsuccessful CVs.
Similarly, the recurrence rate of AF after CV was slightly lower in
patients with AF lasting 24 to 48 hours when compared with patients
with AF lasting <24 hours.
The number of TE events, deaths, and acute arrhythmic complica-
tions was scant and in line with prior studies,14,17,18 and these adverse
TABLE 2 Adverse outcomes of CVs according to duration of index episode of AF
Outcomes AF <24 h, n = 1767 AF 24–48 h, n = 516 AF 48 h–30 d, n = 632 AF >30 d, n = 1441 P Value, H-L Test
Composite adverse outcome 645 (36.5) 160 (31.1) 283 (45.0) 581 (40.4) <0.01
Adjusted OR (95% CI) 1.33 (1.07–1.66) Ref 2.00 (1.52–2.60) 1.89 (1.49–2.40) 0.37
Unsuccessful CV 150 (8.5) 28 (5.4) 70 (11.1) 200 (13.9) <0.01
Adjusted OR (95% CI) 1.81 (1.16–2.84) Ref 2.10 (1.17–3.60) 3.60 (2.27–5.90) 0.74
Asystole >5 s 15 (0.8) 4 (0.8) 6 (0.9) 7 (0.5) 0.58
Adjusted OR (95% CI) 1.00 (0.33–3.03) Ref 1.24 (0.33–4.65) 0.54 (0.15–1.92) 0.84
TE event 2 (0.1) 0 (0.0) 0 (0.0) 3 (0.2) 0.29
Adjusted OR (95% CI) — Ref — — —
Mortality 0 (0.0) 1 (0.2) 0 (0.0) 3 (0.2) 0.18
Adjusted OR (95% CI) — Ref — — —
AF recurrence 481 (29.8) 129 (26.5) 209 (37.3) 375 (30.3) <0.01
Adjusted OR (95% CI) 1.23 (0.97–1.56) Ref 1.83 (1.36–2.46) 1.64 (1.25–2.14) 0.26
Abbreviations: AF, atrial fibrillation; CI, confidence interval; CV, cardioversion; H-L, Hosmer-Lemeshow; OR, odds ratio; Ref, reference; TE, thromboem-
bolic. Data are presented as n (%).
TABLE 1 Baseline characteristics of CVs according to duration of index episode of AF
AF <24 h, n = 1767 AF 24–48 h, n = 516 AF 48 h–30 d, n = 632 AF >30 d, n = 1441 P Value
Age, y
Mean 64  12 64 10 63 11 64 10 <0.01
Median (IQR) 66 (60–73) 64 (59–71) 63 (56–70) 65 (58–72) <0.01
> 75 294 (16.7) 62 (12.1) 73 (12.7) 223 (16.7) <0.01
Female sex 796 (45.0) 197 (38.2) 159 (25.2) 401 (28.2) <0.01
Prior cardioversiona 1301 (75.8) 330 (69.6) 246 (81.5) 347 (49.2) <0.01
CHA2DS2-VASc-score ≥ 2 1190 (67.3) 327 (63.4) 305 (48.3) 766 (53.2) <0.01
Ventricular rate < 60 bpm 23 (1.4) 12 (2.5) 16 (3.0) 46 (3.5) <0.01
Median (IQR) 109 (92–125) 102 (88–120) 91 (77–110) 86 (75–100) <0.01
History of HF 147 (8.3) 66 (12.8) 110 (17.7) 193 (13.8) <0.01
HTN 989 (56.0) 271 (52.5) 295 (47.0) 775 (54.3) <0.01
CKD 34 (1.9) 13 (2.5) 29 (4.7) 70 (5.1) <0.01
DM 226 (12.8) 81 (15.7) 87 (13.9) 213 (15.2) 0.18
Cirrhosis 0 (0.0) 2 (0.4) 0 (0.0) 4 (0.3) 0.49
Prior stroke 244 (13.8) 58 (11.3) 31 (5.0) 39 (2.8) <0.01
CAD 632 (35.8) 178 (34.5) 78 (12.6) 164 (11.7) <0.01
Prior MI 201 (11.4) 73 (14.1) 43 (6.9) 88 (6.3) <0.01
PAD 475 (26.9) 131 (25.5) 19 (3.1) 26 (1.9) <0.01
Pacemaker 157 (8.9) 58 (11.3) 67 (11.0) 69 (5.0) <0.01
Medication at CV
β-Blocker 1542 (87.3) 430 (83.5) 543 (86.2) 1262 (88.0) 0.06
Digoxin 175 (9.9) 58 (11.5) 88 (15.3) 246 (19.4) <0.01
Verapamil 37 (2.1) 17 (3.4) 4 (0.7) 13 (1.0) <0.01
Any antiarrhythmic agentb 466 (26.4) 132 (26.1) 132 (22.9) 122 (9.7) <0.01
Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CHA2DS2-VASc, congestive HF, HTN, age ≥ 75 years (doubled), DM, prior stroke/TIA/
TE (doubled), vascular disease, age 65–74 years, and sex category (female, unless age < 65 years and no other risk factors); CKD, chronic kidney disease;
CV, cardioversion; DM, diabetes mellitus; HF, heart failure; HTN, hypertension; IQR, interquartile range; MI, myocardial infarction; PAD, peripheral arterial
disease; SD, standard deviation; TE, thromboembolism; TIA, transient ischemic attack. Data are presented as n (%), mean  SD, or median (IQR).
a Data are missing in 1158 (26.6) cases.
b Antiarrhythmic agents comprised flecainide, amiodarone, propafenone, quinidine, or disopyramide, and dronedarone.
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events were not associated with AF episode duration. Prior studies
have, however, suggested that elective CV of AF lasting >48 hours
introduces patients to 5-fold risk (~0.5% for the post-CV month) for
TE events despite anticoagulation, compared with overall low risk in
patients on OAC (0.1%/mo). Although recent data suggest that this
extra risk associated with elective CV of AF lasting >48 hours could
be countered with more intensive anticoagulation,19 non-
anticoagulated AF patients should be referred for prompt (preferably
<12 h) rhythm conversion, because shorter delay to CV has been tied
to a lower risk of stroke.6
Although there appears to be relatively few safety issues with the
CV procedure itself in appropriately anticoagulated patients, there is
substantially more room for improvement with efficacy outcomes
after CV for AF. The composite adverse outcome was largely driven
by the efficacy endpoints (ie, the rates of unsuccessful CV and recur-
rence of AF after CV). Modifiable independent risk factors for the
composite adverse outcome were scarce, and this further underscores
the importance of minimizing the delay between AF diagnosis and CV
in rhythm management of AF. This view is supported by the data anal-
ysis revealing lower efficacy outcomes in patients with AF episodes of
unknown duration (see Supporting Information, Table S1, in the online
version of this article).
4.1 | Study limitations
The major limitations of our study are related to the retrospective
setup. First, the inclusion of study population from 3 different cohorts
may cause imbalance in the study cohort. Nevertheless, patients were
from the same hospitals and catchment areas, and CV procedures
were performed using a standardized protocol. Second, the definition
of index episode duration is subjective; this is why we excluded
patients with unknown AF index episode duration from the main anal-
ysis but provided the data in the Supporting Information. Despite
these limitations, we believe that these data can guide future research
and treatment decisions in patients undergoing CV.
5 | CONCLUSION
Our findings provide evidence that the longer delay from AF onset to
CV is associated with reduced procedural success rate together with
increased AF recurrence after successful CV. Sooner seems better in
scheduling CV for patients in rhythm management of AF.
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